May 17, 2019 - Fierce Biotech
Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus
deal
to work with Parvus on drugs to treat autoimmune diseases.
May 17, 2019 - Fierce Pharma
A biologics arms race of sorts appears to be shaping up in South Korea. Celltrion Chairman Seo Jung-jin said on Thursday that the conglomerate will spend about $33.6 billion on its pharma business over the next decade. The pledge comes just months after competitor Samsung said it will spend $22 billion in much the same way.
May 15, 2019 - The Wall Street Journal
The administration is strongly interested in forcing insurers to publicize the negotiated rates they pay for services. The requirement could affect insurers providing coverage in the private-employer market, where about 158 million people get their health insurance.
May 15, 2019 - Fierce Pharma
After snagging the first Japanese CAR-T approval in March, Novartis has won the go-ahead to sell its groundbreaking med, Kymriah, under the country’s national insurance system. And that gives the brand a chance to boost lagging sales. The price makes Kymriah the
most expensive
treatment offered by the Japanese public insurance system.
May 15, 2019 - Fierce Biotech
Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage
deal
features more than $1 billion in milestones tied to the success of six programs.
May 13, 2019 - Fierce Biotech
The idea is to provide a centralized R&D and manufacturing team for its portfolio companies to bring cell and gene therapies “from bench to bedside." ElevateBio is partnering with academic researchers, medical centers and entrepreneurs to create those companies.
May 13, 2019 - Bio Pharma Dive
Bayer plans on spending $150 million to create a new 40,000-square-foot facility for biologics development and manufacturing. The Cell Culture Technology Center will be
built on
Bayer's campus in Berkeley, California, and focus primarily on biologic therapies for oncology, cardiology and additional specialty care areas.
